Form 4: Aclaris Therapeutics CFO Kevin Balthaser Reports Stock Transactions
SEC Form 4 Filing
Kevin Balthaser, CFO of Aclaris Therapeutics, reports multiple transactions involving common stock and restricted stock units.
Summary
- On March 1st and 2nd, 2024, Kevin Balthaser, the CFO of Aclaris Therapeutics, engaged in multiple transactions involving the company's common stock and restricted stock units.
- These transactions included the vesting and settlement of restricted stock units, as well as the withholding of shares by the issuer to satisfy tax obligations.
- Specifically, on March 1st, 1,100 and 2,375 restricted stock units vested, and on March 2nd, 1,500 restricted stock units vested.
- The CFO now directly owns 23,983 shares of Aclaris Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CFO's stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of Power of Attorney execution |
| 03/01/2023 | Initial vesting date for some restricted stock units |
| 03/01/2024 | Transaction date for common stock and restricted stock units |
| 03/02/2023 | Initial vesting date for some restricted stock units |
| 03/02/2024 | Transaction date for common stock and restricted stock units |
| 03/01/2025 | Final vesting date for some restricted stock units |
| 03/05/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.